알레르기 면역치료 시장 : 세계 산업 분석, 규모, 점유율, 성장, 동향 및 예측(2023-2031년)

Allergy Immunotherapy Market - Scope of Report

TMR's report on the global allergy immunotherapy market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2023 to 2031. The report provides revenue of the global allergy immunotherapy market for the period 2017-2031, considering 2023 as the base year and 2031 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global allergy immunotherapy market from 2023 to 2031.

The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players' product literature, annual reports, press releases, and relevant documents to understand the allergy immunotherapy market.

Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global allergy immunotherapy market.

The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report throws light on the changing competitive dynamics in the global allergy immunotherapy market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global allergy immunotherapy market.

The report delves into the competitive landscape of the global allergy immunotherapy market. Key players operating in the global allergy immunotherapy market have been identified and each one of these has been profiled in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are the attributes of players in the global allergy immunotherapy market profiled in this report.

Key Questions Answered in Global allergy immunotherapy Market Report:

• What is the sales/revenue generated by allergy immunotherapy across all regions during the forecast period?
• What are the opportunities in the global allergy immunotherapy market?
• What are the major drivers, restraints, opportunities, and threats in the market?
• Which regional market is set to expand at the fastest CAGR during the forecast period?
• Which segment is expected to generate the highest revenue globally in 2031?
• Which segment is projected to expand at the highest CAGR during the forecast period?
• What are the market positions of different companies operating in the global market?

Allergy Immunotherapy Market - Research Objectives and Research Approach

The comprehensive report on the global allergy immunotherapy market begins with an overview, followed by the scope and objectives of the study. The report provides detailed explanation of the objectives behind this study and key vendors and distributors operating in the market and regulatory scenario for approval of products.

For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into smaller ones. The report comprises an exhaustive collection of graphs and tables that are appropriately interspersed. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the market shares of key segments in the past and at the end of the forecast period.

The report analyzes the global allergy immunotherapy market in terms of product, end-user, and region. Key segments under each criterion have been studied at length, and the market share for each of these at the end of 2031 has been provided. Such valuable insights enable market stakeholders in making informed business decisions for investment in the global allergy immunotherapy market.

Table of Contents

1. Preface

• 1.1. Market Definition and Scope
• 1.2. Market Segmentation
• 1.3. Key Research Objectives
• 1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Global Allergy Immunotherapy Market

4. Market Overview

• 4.1. Introduction
  • 4.1.1. Product Definition
  • 4.1.2. Industry Evolution / Developments
• 4.2. Overview
• 4.3. Market Dynamics
  • 4.3.1. Drivers
  • 4.3.2. Restraints
  • 4.3.3. Opportunities
• 4.4. Global Allergy Immunotherapy Market Analysis and Forecast, 2017-2031
• 4.5. Porter's Five Force Analysis

5. Key Insights

• 5.1. COVID-19 Pandemic Impact on Industry

6. Global Allergy Immunotherapy Market Analysis and Forecast, by Treatment

• 6.1. Introduction & Definition
• 6.2. Key Findings / Developments
• 6.3. Market Value Forecast, by Treatment, 2017-2031
  • 6.3.1. Subcutaneous Immunotherapy (SCIT)
  • 6.3.2. Sublingual Immunotherapy (SLIT)
• 6.4. Market Attractiveness Analysis, by Treatment

7. Global Allergy Immunotherapy Market Analysis and Forecast, by Allergy Type

• 7.1. Introduction & Definition
• 7.2. Key Findings / Developments
• 7.3. Market Value Forecast, by Allergy Type, 2017-2031
  • 7.3.1. Allergic Rhinitis
  • 7.3.2. Asthma
  • 7.3.3. Food Allergy
  • 7.3.4. Venom Allergy
  • 7.3.5. Others
• 7.4. Market Attractiveness Analysis, By Allergy Type

8. Global Allergy Immunotherapy Market Analysis and Forecast, by Distribution Channel

• 8.1. Introduction & Definition
• 8.2. Key Findings / Developments
• 8.3. Market Value Forecast, by Distribution Channel, 2017-2031
  • 8.3.1. Hospital Pharmacies
  • 8.3.2. Retail Pharmacies & Drug Stores
  • 8.3.3. Online Pharmacies
• 8.4. Market Attractiveness Analysis, By Distribution Channel

9. Global Allergy Immunotherapy Market Analysis and Forecast, by Region

• 9.1. Key Findings
• 9.2. Market Value Forecast, by Region
  • 9.2.1. North America
  • 9.2.2. Europe
  • 9.2.3. Asia Pacific
  • 9.2.4. Latin America
  • 9.2.5. Middle East & Africa
• 9.3. Market Attractiveness Analysis, by Region

10. North America Allergy Immunotherapy Market Analysis and Forecast

• 10.1. Introduction
  • 10.1.1. Key Findings
• 10.2. Market Value Forecast, by Treatment, 2017-2031
  • 10.2.1. Subcutaneous Immunotherapy (SCIT)
  • 10.2.2. Sublingual Immunotherapy (SLIT)
• 10.3. Market Value Forecast, by Allergy Type, 2017-2031
  • 10.3.1. Allergic Rhinitis
  • 10.3.2. Asthma
  • 10.3.3. Food Allergy
  • 10.3.4. Venom Allergy
  • 10.3.5. Others
• 10.4. Market Value Forecast, by Distribution Channel, 2017-2031
  • 10.4.1. Hospital Pharmacies
  • 10.4.2. Retail Pharmacies & Drug Stores
  • 10.4.3. Online Pharmacies
• 10.5. Market Value Forecast, by Country, 2017-2031
  • 10.5.1. U.S.
  • 10.5.2. Canada
• 10.6. Market Attractiveness Analysis
  • 10.6.1. By Treatment
  • 10.6.2. By Allergy Type
  • 10.6.3. By Distribution Channel
  • 10.6.4. By Country

11. Europe Allergy Immunotherapy Market Analysis and Forecast

• 11.1. Introduction
  • 11.1.1. Key Findings
• 11.2. Market Value Forecast, by Treatment, 2017-2031
  • 11.2.1. Subcutaneous Immunotherapy (SCIT)
  • 11.2.2. Sublingual Immunotherapy (SLIT)
• 11.3. Market Value Forecast, by Allergy Type, 2017-2031
  • 11.3.1. Allergic Rhinitis
  • 11.3.2. Asthma
  • 11.3.3. Food Allergy
  • 11.3.4. Venom Allergy
  • 11.3.5. Others
• 11.4. Market Value Forecast, by Distribution Channel, 2017-2031
  • 11.4.1. Hospital Pharmacies
  • 11.4.2. Retail Pharmacies & Drug Stores
  • 11.4.3. Online Pharmacies
• 11.5. Market Value Forecast, by Country/Sub-region, 2017-2031
  • 11.5.1. Germany
  • 11.5.2. U.K.
  • 11.5.3. France
  • 11.5.4. Italy
  • 11.5.5. Spain
  • 11.5.6. Rest of Europe
• 11.6. Market Attractiveness Analysis
  • 11.6.1. By Treatment
  • 11.6.2. By Allergy Type
  • 11.6.3. By Distribution Channel
  • 11.6.4. By Country/Sub-region

12. Asia Pacific Allergy Immunotherapy Market Analysis and Forecast

• 12.1. Introduction
  • 12.1.1. Key Findings
• 12.2. Market Value Forecast, by Treatment, 2017-2031
  • 12.2.1. Subcutaneous Immunotherapy (SCIT)
  • 12.2.2. Sublingual Immunotherapy (SLIT)
• 12.3. Market Value Forecast, by Allergy Type, 2017-2031
  • 12.3.1. Allergic Rhinitis
  • 12.3.2. Asthma
  • 12.3.3. Food Allergy
  • 12.3.4. Venom Allergy
  • 12.3.5. Others
• 12.4. Market Value Forecast, by Distribution Channel, 2017-2031
  • 12.4.1. Hospital Pharmacies
  • 12.4.2. Retail Pharmacies & Drug Stores
  • 12.4.3. Online Pharmacies
• 12.5. Market Value Forecast, by Country/Sub-region, 2017-2031
  • 12.5.1. China
  • 12.5.2. India
  • 12.5.3. Japan
  • 12.5.4. Australia & New Zealand
  • 12.5.5. Rest of Asia Pacific
• 12.6. Market Attractiveness Analysis
  • 12.6.1. By Treatment
  • 12.6.2. By Allergy Type
  • 12.6.3. By Distribution Channel
  • 12.6.4. By Country/Sub-region

13. Latin America Allergy Immunotherapy Market Analysis and Forecast

• 13.1. Introduction
  • 13.1.1. Key Findings
• 13.2. Market Value Forecast, by Treatment, 2017-2031
  • 13.2.1. Subcutaneous Immunotherapy (SCIT)
  • 13.2.2. Sublingual Immunotherapy (SLIT)
• 13.3. Market Value Forecast, by Allergy Type, 2017-2031
  • 13.3.1. Allergic Rhinitis
  • 13.3.2. Asthma
  • 13.3.3. Food Allergy
  • 13.3.4. Venom Allergy
  • 13.3.5. Others
• 13.4. Market Value Forecast, by Distribution Channel, 2017-2031
  • 13.4.1. Hospital Pharmacies
  • 13.4.2. Retail Pharmacies & Drug Stores
  • 13.4.3. Online Pharmacies
• 13.5. Market Value Forecast, by Country/Sub-region, 2017-2031
  • 13.5.1. Brazil
  • 13.5.2. Mexico
  • 13.5.3. Rest of Latin America
• 13.6. Market Attractiveness Analysis
  • 13.6.1. By Treatment
  • 13.6.2. By Allergy Type
  • 13.6.3. By Distribution Channel
  • 13.6.4. By Country/Sub-region

14. Middle East & Africa Allergy Immunotherapy Market Analysis and Forecast

• 14.1. Introduction
  • 14.1.1. Key Findings
• 14.2. Market Value Forecast, by Treatment, 2017-2031
  • 14.2.1. Subcutaneous Immunotherapy (SCIT)
  • 14.2.2. Sublingual Immunotherapy (SLIT)
• 14.3. Market Value Forecast, by Allergy Type, 2017-2031
  • 14.3.1. Allergic Rhinitis
  • 14.3.2. Asthma
  • 14.3.3. Food Allergy
  • 14.3.4. Venom Allergy
  • 14.3.5. Others
• 14.4. Market Value Forecast, by Distribution Channel, 2017-2031
  • 14.4.1. Hospital Pharmacies
  • 14.4.2. Retail Pharmacies & Drug Stores
  • 14.4.3. Online Pharmacies
• 14.5. Market Value Forecast, by Country/Sub-region, 2017-2031
  • 14.5.1. GCC Countries
  • 14.5.2. South Africa
  • 14.5.3. Rest of Middle East & Africa
• 14.6. Market Attractiveness Analysis
  • 14.6.1. By Treatment
  • 14.6.2. By Allergy Type

15. Competition Landscape

• 15.1. Market Player - Competition Matrix (By Tier and Size of Companies)
• 15.2. Market Share Analysis, by Company (2021)
• 15.3. Company Profiles
  • 15.3.1. ALK-Abello A/S
    • 15.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
    • 15.3.1.2. Treatment Portfolio
    • 15.3.1.3. Financial Overview
    • 15.3.1.4. SWOT Analysis
    • 15.3.1.5. Strategic Overview
  • 15.3.2. Allergy Therapeutics
    • 15.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
    • 15.3.2.2. Treatment Portfolio
    • 15.3.2.3. Financial Overview
    • 15.3.2.4. SWOT Analysis
    • 15.3.2.5. Strategic Overview
  • 15.3.3. Stallergenes Greer
    • 15.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
    • 15.3.3.2. Treatment Portfolio
    • 15.3.3.3. Financial Overview
    • 15.3.3.4. SWOT Analysis
    • 15.3.3.5. Strategic Overview
  • 15.3.4. HAL Allergy Group
    • 15.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
    • 15.3.4.2. Treatment Portfolio
    • 15.3.4.3. Financial Overview
    • 15.3.4.4. SWOT Analysis
    • 15.3.4.5. Strategic Overview
  • 15.3.5. DBV Technologies
    • 15.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
    • 15.3.5.2. Treatment Portfolio
    • 15.3.5.3. Financial Overview
    • 15.3.5.4. SWOT Analysis
    • 15.3.5.5. Strategic Overview
  • 15.3.6. Merck KGaA
    • 15.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
    • 15.3.6.2. Treatment Portfolio
    • 15.3.6.3. Financial Overview
    • 15.3.6.4. SWOT Analysis
    • 15.3.6.5. Strategic Overview
  • 15.3.7. Aimmune Therapeutics
    • 15.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
    • 15.3.7.2. Treatment Portfolio
    • 15.3.7.3. Financial Overview
    • 15.3.7.4. SWOT Analysis
    • 15.3.7.5. Strategic Overview
  • 15.3.8. Carcassia
    • 15.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
    • 15.3.8.2. Treatment Portfolio
    • 15.3.8.3. Financial Overview
    • 15.3.8.4. SWOT Analysis
    • 15.3.8.5. Strategic Overview
  • 15.3.9. Anergis
    • 15.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
    • 15.3.9.2. Treatment Portfolio
    • 15.3.9.3. Financial Overview
    • 15.3.9.4. SWOT Analysis
    • 15.3.9.5. Strategic Overview
  • 15.3.10. Biomay AG
    • 15.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)
    • 15.3.10.2. Treatment Portfolio
    • 15.3.10.3. Financial Overview
    • 15.3.10.4. SWOT Analysis
    • 15.3.10.5. Strategic Overview